SCHEMBL1794482

SCHEMBL1794482

O=C(c1ccc(CN2CCC3(CC2)CCN(Cc2ccc(F)cc2)C3)cc1)N(Cc1ncc[nH]1)Cc1ncc[nH]1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.77
PRKAA2 P54646 2/20 0.46
KDM1A O60341 1/20 0.44
MAOB P27338 1/20 0.44
RCOR1 Q9UKL0 1/20 0.44
OPRD1 P41143 7/20 0.44
OPRM1 P35372 6/20 0.44
KCNH2 Q12809 3/20 0.43
HTR2B P41595 1/20 0.40
GPR183 P32249 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1792729 1.00 CXCR4 (0.77) CXCR4PRKAA2KDM1AMAOBRCOR1
SCHEMBL1795793 0.91 CXCR4 (0.78) CXCR4KDM1AMAOBRCOR1OPRD1
SCHEMBL1792872 0.91 CXCR4 (0.78) CXCR4KDM1AMAOBRCOR1OPRD1
SCHEMBL1795049 0.91 CXCR4 (0.70) CXCR4PRKAA2KDM1AMAOBRCOR1
SCHEMBL2693219 0.91 CXCR4 (0.80) CXCR4PRKAA2KDM1AMAOBRCOR1
SCHEMBL1795594 0.90 CXCR4 (0.80) CXCR4PRKAA2KDM1AMAOBRCOR1
SCHEMBL2697137 0.90 CXCR4 (0.73) CXCR4KDM1AMAOBRCOR1OPRD1
SCHEMBL1791846 0.90 CXCR4 (0.78) CXCR4KDM1AMAOBRCOR1OPRD1
SCHEMBL1798974 0.89 CXCR4 (0.70) CXCR4PRKAA2KDM1AMAOBRCOR1
SCHEMBL1792948 0.89 CXCR4 (0.74) CXCR4KDM1AMAOBRCOR1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822459-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-02 US disclosed
EP-1790639-B1 SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS ONO PHARMACEUTICAL CO (JP) 2014-03-26 EP disclosed
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2011-06-16 US disclosed
US-7951816-B2 Compound containing basic group and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2011-05-31 US disclosed
US-20080009495-A1 Compound Containing Basic Group and Use Thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2008-01-10 US disclosed
EP-1790639-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110142856-A1 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF CXCR4, CCR5, CXCL12 CXCR4 1/4885PRKAA2 3969/4885KDM1A 4517/4885
US-20080009495-A1 Compound Containing Basic Group and Use Thereof CXCR4, CCR5, CXCR3 CXCR4 1/4885PRKAA2 3992/4885KDM1A 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.